CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company specializing in treatments for age-related neurologic disorders, has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The event will take place in New York on May 20, 2025.
Company management will engage in a fireside chat scheduled from 5:00 to 5:30 PM ET and will also conduct one-on-one investor meetings. The fireside chat will be available via webcast through the company's website and a dedicated event platform.
CervoMed Inc. (NASDAQ: CRVO), un'azienda in fase clinica specializzata in trattamenti per disturbi neurologici legati all'et脿, ha annunciato la sua partecipazione alla 3陋 Conferenza Annuale BioConnect per Investitori di H.C. Wainwright. L'evento si terr脿 a New York il 20 maggio 2025.
Il management dell'azienda parteciper脿 a una conversazione informale programmata dalle 17:00 alle 17:30 ET e terr脿 anche incontri individuali con gli investitori. La conversazione informale sar脿 trasmessa in webcast tramite il sito web dell'azienda e una piattaforma dedicata all'evento.
CervoMed Inc. (NASDAQ: CRVO), una empresa en etapa cl铆nica especializada en tratamientos para trastornos neurol贸gicos relacionados con la edad, ha anunciado su participaci贸n en la 3陋 Conferencia Anual BioConnect para Inversores de H.C. Wainwright. El evento se llevar谩 a cabo en Nueva York el 20 de mayo de 2025.
La direcci贸n de la empresa participar谩 en una charla informal programada de 5:00 a 5:30 PM ET y tambi茅n realizar谩 reuniones individuales con inversores. La charla informal estar谩 disponible v铆a webcast a trav茅s del sitio web de la empresa y una plataforma dedicada al evento.
CervoMed Inc. (NASDAQ: CRVO)電� 鞐半牴 甏�霠� 鞁犼步 歆堩櫂 旃橂鞐� 鞝勲頇旊悳 鞛勳儊 雼硠 須岇偓搿�, H.C. Wainwright 鞝�3須� 鞐半 BioConnect 韴瀽鞛� 須岇潣鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 頄夓偓電� 2025雲� 5鞗� 20鞚� 雺挫殨鞐愳劀 臧滌禍霅╇媹雼�.
須岇偓 瓴届榿歆勳潃 霃欕秬 響滌鞁� 旮办 鞓ろ泟 5鞁滊秬韯� 5鞁� 30攵勱箤歆� 鞓堨爼霅� 牍勱车鞁� 雽�頇旍棎 彀胳棳頃橂┌, 1:1 韴瀽鞛� 氙疙寘霃� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 牍勱车鞁� 雽�頇旊姅 須岇偓 鞗轨偓鞚错姼鞕� 鞝勳毄 鞚措菠韸� 頂岆灚韽检潉 韱淀暣 鞗轨簮鞀ろ姼搿� 鞝滉车霅╇媹雼�.
CervoMed Inc. (NASDAQ : CRVO), une soci茅t茅 en phase clinique sp茅cialis茅e dans les traitements des troubles neurologiques li茅s 脿 l'芒ge, a annonc茅 sa participation 脿 la 3e conf茅rence annuelle BioConnect pour investisseurs de H.C. Wainwright. L'茅v茅nement se tiendra 脿 New York le 20 mai 2025.
La direction de l'entreprise participera 脿 une discussion informelle pr茅vue de 17h00 脿 17h30 (heure de l'Est) et tiendra 茅galement des r茅unions individuelles avec les investisseurs. La discussion informelle sera diffus茅e en webcast via le site web de la soci茅t茅 et une plateforme d茅di茅e 脿 l'茅v茅nement.
CervoMed Inc. (NASDAQ: CRVO), ein klinisch t盲tiges Unternehmen, das sich auf Behandlungen altersbedingter neurologischer Erkrankungen spezialisiert hat, hat seine Teilnahme an der 3. j盲hrlichen BioConnect Investorenkonferenz von H.C. Wainwright angek眉ndigt. Die Veranstaltung findet am 20. Mai 2025 in New York statt.
Die Unternehmensleitung wird an einem Gespr盲ch am Kamin von 17:00 bis 17:30 Uhr ET teilnehmen und zudem Einzelgespr盲che mit Investoren f眉hren. Das Gespr盲ch am Kamin wird 眉ber die Webseite des Unternehmens und eine spezielle Eventplattform per Webcast verf眉gbar sein.
- None.
- None.
BOSTON, May 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 3rd Annual BioConnect Investor Conference being held in New York, NY, on Tuesday, May 20, 2025.
Presentation Details
Format: Fireside Chat
Date: Tuesday, May 20, 2025
Time: 5:00 鈥� 5:30 PM ET
Webcast Link:
The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website .
About CervoMed
CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause clinical disease expression in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.
Investor Contact:
PJ Kelleher
LifeSci Advisors
617-430-7579
FAQ
When is CervoMed (CRVO) presenting at the H.C. Wainwright BioConnect Conference 2025?
What type of company is CervoMed (CRVO)?
How can investors access CervoMed's (CRVO) presentation at the H.C. Wainwright conference?
What activities will CervoMed (CRVO) participate in at the H.C. Wainwright conference?
